Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.

Read more at globenewswire.com